Anti-inflammatory Properties of Macrolide Antibiotics
Helen Kourlas
Abstract
Helen Kourlas
Abstract
The use of macrolide antibiotics for other clinical uses outside of their antimicrobial capabilities has been questioned and theorized in both in vitro and animal studies. Several small clinical trials have shown that erythromycin, clarithromycin, and azithromycin possess anti-inflammatory characteristics in patients with respiratory diseases. To determine whether macrolide antibiotics possess this unique characteristic, data from controlled trials involving human subjects were extracted and analyzed. Conclusions from trials suggest that select macrolide antibiotics possess anti-inflammatory properties in patients with respiratory diseases who do not show evidence of a bacterial infection.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The use of macrolide antibiotics for other clinical uses outside of their antimicrobial capabilities has been questioned and theorized in both in vitro and animal studies. Several small clinical trials have shown that erythromycin, clarithromycin, and azithromycin possess anti-inflammatory characteristics in patients with respiratory diseases. To determine whether macrolide antibiotics possess this unique characteristic, data from controlled trials involving human subjects were extracted and analyzed. Conclusions from trials suggest that select macrolide antibiotics possess anti-inflammatory properties in patients with respiratory diseases who do not show evidence of a bacterial infection.
Key concepts: Azithromycin, Macrolide Antibiotics, Medicine, Antibiotics, Clarithromycin, Erythromycin, Antimicrobial, Clinical trial